Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Aratana Therapeutics must decide if it will continue the development of a treatment candidate for canine osteoarthritis after analyzing the results of a recent study.
US animal health firm Zomedica Pharmaceuticals has achieved a number of milestones for its pet therapeutics pipeline in 2017.
Australian animal health company CannPal has seen its European business prospects boosted with the granting of a small and medium size enterprise status (SME) by the European Medicines Agency (EMA).
Dechra Pharmaceuticals has again returned to Australasia for its latest acquisition.
Jaguar Health has opened up a range of commercial possibilities in the Middle East by securing a collaborative partnership with a notable Dubai-based firm.
Dutch firm Le Vet Pharma has received European approval for two generic companion animal products.
US animal health company Zoetis has increased its canine influenza virus (CIV) vaccine portfolio with a new combination product.
A study of Swedish gene therapy firm Panion's epilepsy drug candidate has shown positive initial results.
One of the European Parliament's leading advocates for improved public health in the EU has said understanding the effects of antibiotics in animal health is pivotal to making progress.
Swedish firm Oasmia Pharmaceuticals is aiming to list its veterinary assets on the Nasdaq through its wholly-owned US subsidiary.
Bayer Animal Health said the growth of companion animals in developing countries has raised the increasing likelihood of pet owners being infected by their pets with zoonotic diseases.
UK firm Dechra Veterinary Products has launched a new complementary pet feed to help cats and dogs suffering with allergic skin conditions.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.